By Albin Stenström, Felipe Estrada, Henrik Tham

Drug use was criminalized in Sweden in 1988 with the aim of reducing the number of consumers and drug-related risks and harms. Imprisonment was introduced into the penalty scale in 1993 to improve the legislation’s effectiveness. The criminalization has never been evaluated. Method: Goal-attainment evaluation based on a range of indicators from surveys, case-finding estimates, healthcare and cause-of-death data, and crime statistics. Comparative drug policy analysis is conducted with other Nordic countries. Results: The criminalization is not followed by a reduced or more expensive drug supply, reduced consumption levels, problematic drug use or healthcare needs, or fewer drug-related deaths. Most of the indicators instead show the opposite. Control costs are high, and trends are no better than those of other Nordic countries, despite Sweden’s more repressive drug policy. Conclusion: Criminalization emerges as an ineffective, expensive, and harmful means of dealing with the drug problem.

International Journal of Drug Policy Volume 133, November 2024, 104573

By Adam Teperski, Stewart Boiteux, and Callan Brown

Aim: To examine trends in drug driving charges, roadside drug testing, and population drug use in New South Wales (NSW) between 2008 and 2023. METHOD Data on drug driving proceedings and roadside drug testing were obtained from the NSW Police Force. Focusing on the period between 2008 and 2023, we describe trends in the number of drug driving charges laid by police, as well as changes in the volume of roadside drug tests undertaken by police and the detection rate over time. We also examine the profile of drivers who are proceeded against after testing positive and any differences in key characteristics over time. Finally, to support the interpretation of these results, we assess changes in drug use from two population drug use monitoring systems and consider associated trends in self-reported drug driving behaviours. RESULTS Between 2008 and 2023, the number of drug driving charges rose from an average of 102 per quarter in 2008 to 3,296 in 2023. This significant growth in charges followed the announcement of two expansions of the NSW Mobile Drug Testing (MDT) program, which resulted in a rapid increase in testing volumes from around 20,000 to 156,000 tests per year in 2008 and 2019 respectively. While the MDT expansions aimed to increase police capacity to detect and deter drug driving behaviours, we found a weak relationship between total testing volumes and subsequent detection rates, with the average detection rate varying between 2% and 18%. This suggests that the number of drug driving charges over this 15-year period was not simply a function of the number of tests conducted, but also related to when, where, and for whom tests were used. When we compared drug driving offenders charged in 2019 with those charged in 2023, we found that the 2023 cohort were more likely to be older, test positive for methamphetamine, reside in regional areas and have a prior drug driving charge. During the period we study, population-level drug use has remained relatively consistent. Meanwhile, the self-reported prevalence of drug driving has decreased at a steady rate, with this downward trend commencing prior to the start of the MDT program in NSW. CONCLUSION Sequential expansions of the MDT program have led to a considerable increase in the number of offenders charged with drug driving offences in NSW between 2008 and 2023. Recent growth in the roadside drug test detection rate and subsequent charges may be driven by police targeting of repeat drug driving offenders, and motorists who offend in regional areas. 

Bureau Brief, No. 172 Sydney, NSW: NSW Bureau of Crime  Statistics and Research. ....2024. 23p.

By Tasha Perdue a, Robert Carlson b, Raminta Daniulaityte c, Sydney M. Silverstein b, Ricky N. Bluthenthal d, Avelardo Valdez e, Alice Cepeda

The purpose of this study is to describe opioid initiation within each of the three waves from the perspective of people who use illicit opioids, with a focus on emerging pathways into fentanyl use. We noted supply-side changes as influencing trajectories in all three waves. However, we also noted differences in the experiences of prescription opioid and heroin initiation, with these trajectories influenced by pharmacological effects, pain management, curiosity, intergenerational use, pricing, and peers. In comparison, most participants were unaware that they were initiating fentanyl, and many reported overdosing with their first use of fentanyl. We identified a trajectory into fentanyl with limited to no prior heroin use among a few participants.

Social Science & Medicine Volume 340. January 2024, 11pg